罗默碱抗前列腺癌活性的实验研究

发布时间：2018-10-12 21:46

【摘要】：目的:构建体外、体内模型,探讨罗默碱抗前列腺癌活性。方法:检测罗默碱对多种前列腺癌细胞(DU145、LNCa P、PC-3和22RV1)增殖、凋亡和迁移的影响,筛选敏感肿瘤细胞系,构建裸鼠荷瘤模型,进一步验证罗默碱的体内抗肿瘤药效。结果:罗默碱对DU145、LNCaP、PC-3和22RV1细胞增殖和迁移均具有不同程度的抑制作用,对其细胞凋亡亦具有不同程度的诱导作用,其中以LNCaP细胞最为敏感。裸鼠荷LNCaP肿瘤模型中,罗默碱单独干预组肿瘤重量[(1.99±0.95)g]显著低于对照组[(2.95±1.04)g],P0.01;而高剂量罗默碱(30 mg/kg)和紫杉醇联合干预组肿瘤重量[(0.90±0.16)g]均显著小于其他3组(P0.05或P0.01)。罗默碱单独干预组裸鼠的心脏脏器系数(0.58±0.06)、肝脏脏器系数(6.20±0.42)和肾脏脏器系数(1.49±0.33)均不同程度低于紫杉醇单独干预组(0.66±0.04、6.99±0.72和1.95±0.34,P均0.05),脾脏脏器系数(0.54±0.11)和胸腺脏器系数(0.06±0.01)显著高于紫杉醇单独干预组(0.41±0.09、0.05±0.01,P均0.05)。病理结果显示罗默碱干预组及联合给药组中肿瘤恶变程度和肿瘤转移程度低于对照组,罗默碱干预组及联合给药组中小鼠内脏损伤明显小于紫杉醇组水平。结论:罗默碱发挥一定的抗前列腺肿瘤功效,同时联合化疗药给药时可以降低其毒性。
[Abstract]:Objective: to study the anti-prostate cancer activity of rommerine in vitro and in vivo. Methods: the effects of rommerine on proliferation, apoptosis and migration of various prostate cancer cells (DU145,LNCa PtPC-3 and 22RV1) were detected, and sensitive tumor cell lines were screened to establish tumor-bearing model in nude mice to further verify the anti-tumor effect of rommerine in vivo. Results: rommerine inhibited the proliferation and migration of DU145,LNCaP,PC-3 and 22RV1 cells in different degrees and induced apoptosis in different degrees. LNCaP cells were the most sensitive. In nude mice bearing LNCaP tumor model, the tumor weight of rommerine alone intervention group [(1.99 卤0.95) g] was significantly lower than that of the control group [(2.95 卤1.04) g, P 0.01], while the tumor weight of high dose rometin (30 mg/kg) and paclitaxel group [(0.90 卤0.16) g] was significantly lower than that of the other three groups (P0.05 or P0.01). The heart organ coefficient (0.58 卤0.06), liver organ coefficient (6.20 卤0.42) and kidney organ coefficient (1.49 卤0.33) in rommerine alone intervention group were lower than those in paclitaxel alone intervention group (0.66 卤0.046.99 卤0.72 and 1.95 卤0.34 P 0.05), spleen organ coefficient (0.54 卤0.11) and thymus organ coefficient (0.06 卤0.01) were significantly lower than those in paclitaxel alone intervention group (0.66 卤0.046.99 卤0.72 and 1.95 卤0.34 P 0.05). It was higher than that of paclitaxel alone (0.41 卤0.09 卤0.05 卤0.01, P 0.05). The pathological results showed that the degree of tumor malignancy and tumor metastasis in rommerine intervention group and combined administration group was lower than that in control group, and the visceral damage in rommerine intervention group and combined administration group was significantly lower than that in paclitaxel group. Conclusion: rommerine can play a certain role in prostatic tumor and decrease its toxicity when combined with chemotherapeutic agents.
【作者单位】：济宁医学院附属医院兖州分院泌尿外科;巨野陶庙卫生院泌尿外科;佳木斯大学附属医院泌尿外科;
【分类号】：R737.25

【相似文献】